Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New guidelines shed light on EGGD
There are distinct differences between EGGD and ‘gastric ulcers’.
Glandular gastric disease is distinct from gastric ulceration

Equine medicine specialists have published new guidelines on equine glandular gastric disease (EGGD), to improve the management of this condition in practice.

There are distinct differences between EGGD and ‘gastric ulcers’. A number of studies now suggest that EGGD is an inflammatory gastritis - predominantly at the gastric outflow - which has different risk factors and causes. As such, treatment for gastric ulceration may be less effective for this specific condition.

A paper published in the new equine veterinary journal, UK Vet: Equine, offers a review of published and unpublished evidence, to give vets up-to-date information on diagnosing and managing the condition.

To reduce EGGD, the authors recommend providing a minimum of two rest days from work per week, or provide regular rest periods. Horses should be turned out where possible, assuming this does not cause stress. Potential stressors, including changes to management, equine companions and human carers, should be minimised. Two litres of chaff or equivalent volume of of forage should also be fed 30 minutes before exercise.

Clinical signs are diverse, non-specific and may be mild or recurrent. Authors identified the following potential signs: changes in temperament including nervousness or aggression; changes in ride-ability such as reduced willingness to work and reluctance to go forward; unexplained weight loss, reduced appetite or altered eating patterns; colic; and cutaneous sensitivity, manifesting as flank biting or resentment of girthing, grooming, leg aids or rugging.

Based on current evidence, authors recommend the use of one of three first-line treatment options:
  • Oral omeprazole at 4mg/kg PO SID with sucralfate at 12mg/kg PO BID. Feed must be withheld for a minimum of eight hours before and 30 minutes after omeprazole is administered, and sucralfate must be administered at least 30 minutes after the omeprazole.  
  • Misoprostol at 5μg/kg PO BID. However, misoprostol has the potential to induce abortion in humans, so this option may not be appropriate if there are concerns over human exposure.
  • Long-acting omeprazole at 4mg/kg IM every five to seven days.

It is recommended that one of these three first-line treatment protocols should be selected on a case-by-case basis. All three options require the use of unlicensed medicines, so these should be used in accordance with the prescribing cascade. Further options are proposed for cases that are resistant to treatment.

Gastroscopic examinations are advised every month during treatment to assess the patient’s response. If there is no improvement at three months, authors say biopsy and investigation for other diseases should be considered. Frequent changes to the treatment regimen should be avoided and clinical signs monitored carefully during and after treatment.

The authors acknowledged that many of the recommendations are based on ‘weak evidence or expert opinion’. With this in mind they urge all stakeholders to support research into EGGD, to allow more evidence-based recommendations to be made in future.

 

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.